Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029263661> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W3029263661 endingPage "441" @default.
- W3029263661 startingPage "437" @default.
- W3029263661 abstract "ObjectiveTo observe and compare the curative effects of zoledronic acid (ZA) combined with radiotherapy and ZA combined with chemotherapy in the treatment of bone metastasis of non-small cell lung cancer (NSCLC).MethodsSeventy-eight patients with NSCLC bone metastasis treated by radiotherapy or chemotherapy were taken in our hospital from January 2010 to June 2014, including 39 cases of ZA combined conventional fractionation radiotherapy (radiotherapy combined group), and 39 cases of ZA combined with chemotherapy (paclitaxel liposome + cisplatin) (chemotherapy combined group). Each group had 39 cases. WHO objective evaluation standard, efficacy evalulation of solid tumor metastasis and curative effect standard grading of pain, anticancer agent toxicity classification standard, Karnofsky standard were used for evaluating and analyzing the patients with primary lung tumor, bone metastasis, degree of pain, adverse reactions and functional status (once before and after the treatment).ResultsThe efficiency rate of primary lung tumor, the efficiency rate of bone metastasis, the total effective rate of pain relief and the improvement rate of functional status (Karnofsky score increased by 10 points or more)in the radiotherapy combined group and chemotherapy combined group were 82.05 % (32/39) vs. 79.49 % (31/39), 48.72 % (19/39) vs. 51.28 % (20/39), 82.05 % (32/39) vs. 84.62 % (33/39), 66.67 % (26/39) vs. 71.79 % (28/39) respectively, and the differences were not statistically significant (the values of χ2 were 0.224, 0.237, 0.195, 0.259 respectively, all P > 0.05); Although the two groups showed low-grade fever, bone marrow suppression, esophagitis, liver and kidney damage, gastrointestinal reactions and other adverse reactions, the adverse reactions of two groups were close to [28.21 % (11/39) vs. 30.77 % (12/39)] (χ2= 0.314, P > 0.05). Fortunately, these reactions were controlled well after symptomatic treatment.ConclusionZA combined with radiotherapy or chemotherapy is a safe and effective way for bone metastasis of NSCLC, which should be taken based on the individual condition of the patients.Key words: Carcinoma, non-small-cell lung; Radiotherapy, computer-assisted; Drug therapy, combination; Neoplasm metastasis; Zoledronic acid" @default.
- W3029263661 created "2020-06-05" @default.
- W3029263661 creator A5003173777 @default.
- W3029263661 creator A5031154818 @default.
- W3029263661 creator A5037400952 @default.
- W3029263661 creator A5072050853 @default.
- W3029263661 date "2017-07-28" @default.
- W3029263661 modified "2023-09-26" @default.
- W3029263661 title "Efficacy analysis of zoledronic acid combined with radiotherapy and combined with chemotherapy for bone metastasis of non-small cell lung cancer" @default.
- W3029263661 doi "https://doi.org/10.3760/cma.j.issn.1006-9801.2017.07.002" @default.
- W3029263661 hasPublicationYear "2017" @default.
- W3029263661 type Work @default.
- W3029263661 sameAs 3029263661 @default.
- W3029263661 citedByCount "0" @default.
- W3029263661 crossrefType "journal-article" @default.
- W3029263661 hasAuthorship W3029263661A5003173777 @default.
- W3029263661 hasAuthorship W3029263661A5031154818 @default.
- W3029263661 hasAuthorship W3029263661A5037400952 @default.
- W3029263661 hasAuthorship W3029263661A5072050853 @default.
- W3029263661 hasConcept C121608353 @default.
- W3029263661 hasConcept C126322002 @default.
- W3029263661 hasConcept C141071460 @default.
- W3029263661 hasConcept C143998085 @default.
- W3029263661 hasConcept C2776256026 @default.
- W3029263661 hasConcept C2776326535 @default.
- W3029263661 hasConcept C2776694085 @default.
- W3029263661 hasConcept C2777783956 @default.
- W3029263661 hasConcept C2778239845 @default.
- W3029263661 hasConcept C2779013556 @default.
- W3029263661 hasConcept C509974204 @default.
- W3029263661 hasConcept C71924100 @default.
- W3029263661 hasConceptScore W3029263661C121608353 @default.
- W3029263661 hasConceptScore W3029263661C126322002 @default.
- W3029263661 hasConceptScore W3029263661C141071460 @default.
- W3029263661 hasConceptScore W3029263661C143998085 @default.
- W3029263661 hasConceptScore W3029263661C2776256026 @default.
- W3029263661 hasConceptScore W3029263661C2776326535 @default.
- W3029263661 hasConceptScore W3029263661C2776694085 @default.
- W3029263661 hasConceptScore W3029263661C2777783956 @default.
- W3029263661 hasConceptScore W3029263661C2778239845 @default.
- W3029263661 hasConceptScore W3029263661C2779013556 @default.
- W3029263661 hasConceptScore W3029263661C509974204 @default.
- W3029263661 hasConceptScore W3029263661C71924100 @default.
- W3029263661 hasIssue "07" @default.
- W3029263661 hasLocation W30292636611 @default.
- W3029263661 hasOpenAccess W3029263661 @default.
- W3029263661 hasPrimaryLocation W30292636611 @default.
- W3029263661 hasVolume "29" @default.
- W3029263661 isParatext "false" @default.
- W3029263661 isRetracted "false" @default.
- W3029263661 magId "3029263661" @default.
- W3029263661 workType "article" @default.